New insider activity at Precigen ( (PGEN) ) has taken place on September 30, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Precigen stock, Director Randal Kirk made a significant move by selling 1,809,667 shares, amounting to a total of $6,170,964. On the other hand, CCO Phil Tennant showed confidence in the company’s future by purchasing 6,000 shares, valued at $21,480.
Recent Updates on PGEN stock
Precigen has recently announced significant corporate developments, including the conversion of preferred stock into common stock and securing a $125 million loan facility with Pharmakon Advisors. The stock conversion is part of the company’s strategic financial restructuring, while the loan aims to support the commercialization of their novel immunotherapy, PAPZIMEOS. Despite these positive corporate events and strong technical momentum, analysts maintain a Hold rating due to concerns over the company’s financial performance and valuation. The financial instability, despite the potential growth from product approvals and strategic moves, remains a significant risk factor influencing the stock’s price target.
Spark’s Take on PGEN Stock
According to Spark, TipRanks’ AI Analyst, PGEN is a Neutral.
Precigen’s overall stock score reflects a mix of strong technical momentum and positive corporate events, offset by weak financial performance and valuation concerns. The company’s recent strategic moves and product approvals provide growth potential, but financial instability remains a significant risk.
To see Spark’s full report on PGEN stock, click here.
More about Precigen
YTD Price Performance: 236.11%
Average Trading Volume: 8,678,604
Technical Sentiment Signal: Buy
Current Market Cap: $1.08B